The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Atezolizumab and Bevacizumab in Hepatocellular Carcinoma (HCC)

Combination immunotherapy and antiangiogenic therapy for advanced liver cancer

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Atezolizumab and Bevacizumab in Hepatocellular Carcinoma (HCC)?

Atezolizumab is humanized anti-PD-L1 monoclonal antibody restoring T-cell antitumor immune response by blocking PD-L1 binding to PD-1 and B7.1.

Bevacizumab is anti-VEGF monoclonal antibody inhibiting tumor angiogenesis with potential immune-modulating effects supporting combination synergy.

First-line indication for unresectable hepatocellular carcinoma in patients with preserved liver function (Child-Pugh A) and good performance status.

IMbrave150 trial demonstrated superior outcomes compared to sorafenib establishing combination as new standard of care.

Treatment continued every 3 weeks until disease progression, unacceptable toxicity or development of contraindications.

Symptoms

Bevacizumab-related effects include hypertension, proteinuria, epistaxis, fatigue and rare but serious gastrointestinal perforation, thromboembolism and bleeding.
Esophageal variceal bleeding particularly concerning in cirrhotic patients requiring pretreatment screening and management.
Atezolizumab-related immune events including fatigue, rash, hepatitis (particular concern in HCC), endocrinopathies, pneumonitis and colitis.
Hepatic decompensation may occur requiring careful monitoring of liver function throughout treatment.
Combined effects may include synergistic toxicities requiring multidisciplinary management.

Risk Factors

Decompensated cirrhosis (Child-Pugh B or C) generally precludes treatment due to hepatotoxicity risk.
Esophageal varices particularly high-risk varices require pretreatment endoscopy and treatment.
Recent bleeding history within 6 months precludes bevacizumab use due to bleeding risk.
Major surgery within 28 days affects timing of bevacizumab initiation.
Active autoimmune disease may limit immunotherapy use though not absolute contraindication.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New jaundice, ascites, encephalopathy or other signs of hepatic decompensation require urgent hepatologic evaluation.
  • Hematemesis, melena or other bleeding requires immediate emergency evaluation.
  • Severe hypertension, proteinuria or thromboembolic events require urgent assessment.
  • Symptoms suggesting immune-related adverse events warrant evaluation and possible immunosuppressive therapy.
  • Performance status decline or comorbidity development may warrant treatment reconsideration.

Treatment Methods

01
Pretreatment evaluation including endoscopy with esophageal varices treatment, liver function assessment and complete medical history.
02
Routine monitoring with blood pressure, urine protein, complete metabolic panel including liver function, complete blood count and clinical evaluation.
03
Patient education regarding immune-related adverse events, bleeding risk, hypertension monitoring and prompt symptom reporting.
04
Treatment of bevacizumab-related effects including antihypertensives, urinalysis monitoring and bleeding precautions.
05
Multidisciplinary care including oncology, hepatology, gastroenterology and other specialties along with consideration of liver disease management, locoregional therapy in selected patients, subsequent line therapies and supportive care optimizes outcomes for this transformative combination.

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.